French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year’s annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).